Rather, our results suggest that increased HER2 gene dosage resulting from gene amplification is the most important determinant of HER2 overexpression, whereas any influence resulting from polysomy for chromosome 17 alone is unlikely to play a significant role in HER2 gene overexpression at the transcriptional level; a similar finding was described previously in breast cancer [12]. This evidence concerns the gene ERBB2 and breast cancer.